Optimum’s 15th Annual Healthcare Investor Conference 2023 | Save the date
6TH OCTOBER 2022 | LONDON
6TH OCTOBER 2022 | LONDON
14 February 2023 – Optimum Strategic Communications (“Optimum”), the specialist life sciences communications consultancy, today announces that it has hired Jonathan Edwards and Hana Malik, two highly experienced investor relations and communications professionals, to join as permanent members of its team. Edwards and Malik have joined Optimum as Account Directors and will be advising clients across […]
The Novo Holdings Venture Investments team has published its 2023 newsletter today. It is one of the largest and most active international life science venture investors with a track record of over 20 years investing in novel therapies. For more information, please see Venture Investments 2023 Newsletter.
alfapump® – successful primary endpoint read-out of North American pivotal POSEIDON study / PMA[1] filing planned for H2 2023 DSR® (Direct Sodium Removal) – clinical evidence of disease-modifying heart failure drug therapy, on track to start US Phase 1/2a MOJAVE study in Q2 2023 Total cash position of €18.9 million at end 2022 and cash runway […]
Zwingenberg/Neuried, February 8, 2023 – Creating a better future with biotechnology – this vision is shared by BRAIN Biotech AG (BRAIN Biotech), a leader in the development and manufacture of bio-based solutions and products for industry, and AMSilk GmbH (AMSilk), the world’s first industrial supplier of innovative biomaterials for more sustainable applications in the textile, medical […]